Emles Advisors Announces Closure of Six Funds PR Newswire NEW YORK, Sept. 16, 2022 NEW YORK, Sept. 16, 2022 /PRNewswire/ -- Due to the inability to attract sufficient investment assets and based...
Samaritan Pharmaceuticals Inc. (AMEX:LIV): ? -- Trial Designed to Tackle HIV Drug Resistance (One or More of a Patient's Current HIV Drug Regime Stops Working Leading to a Lack of Treatment...
Samaritan Pharmaceuticals Inc. (AMEX:LIV): ? -- Data Shows 0.4 log10 Difference Between the High-Dose and the Placebo Control Group ? -- Dose dependent relationship in the number of subjects...
Samaritan Pharmaceuticals Inc. (AMEX:LIV): ? -- Clears Clogged Arteries ? -- Raises HDL ? -- Reduces CK Enzyme Marker: Suggesting It Improves, Hypercholesterolemia-Related Heart Suffering...
Samaritan Pharmaceuticals (AMEX:LIV): ? -- Completed Phase II Stage 1 (10 Day Monotherapy) ? -- Expect to Report Stage I Preliminary Results at Shareholders Meeting May 31st ? -- Expect...
The Samaritan Foundation and Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, announced today on National DNA day, it is driven to raise money to bring its...
Samaritan Pharmaceuticals Inc. (AMEX:LIV) ? -- David W. Munno, Merrill Lynch VP of biotechnology, stated, "Large-cap biotech firms need some blockbuster products for meaningful growth which is...
Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative drugs, announced today, its shareholders are invited to the Annual Shareholders Meeting on Wednesday, May 31, 2006 10 a.m. at...
Samaritan Pharmaceuticals, Inc. (AMEX:LIV) is pleased to announce that its subsidiary Samaritan Pharmaceuticals Europe, S.A. has received notification by the National Pharmaceuticals Organization...
Samaritan Pharmaceuticals Inc. (AMEX:LIV): ? -- PII/III HIV Oral Entry Inhibitor Drug ? -- Cardiovascular Drug SP-1000 ? -- Alzheimer's Drug SP-233 ? -- Alzheimer's Blood Diagnostic ?...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales